Prostate Neoplasm Clinical Trials

11 recruiting

Prostate Neoplasm Trials at a Glance

14 actively recruiting trials for prostate neoplasm are listed on ClinicalTrialsFinder across 6 cities in 19 countries. The largest study group is Not Applicable with 4 trials, with the heaviest enrollment activity in Houston, New York, and Barcelona. Lead sponsors running prostate neoplasm studies include Janssen Research & Development, LLC, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, and Eli Lilly and Company.

Browse prostate neoplasm trials by phase

Treatments under study

About Prostate Neoplasm Clinical Trials

Looking for clinical trials for Prostate Neoplasm? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Prostate Neoplasm trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Prostate Neoplasm clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Not Applicable

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

Prostate CancerProstate NeoplasmProstate Adenocarcinoma
University of Chicago180 enrolled1 locationNCT05710380
Recruiting
Phase 1

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Breast NeoplasmsColorectal NeoplasmsProstate Neoplasm+2 more
Eli Lilly and Company421 enrolled28 locationsNCT07114601
Recruiting

Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion and Non-Contrast MRI

Prostate Neoplasm
Mayo Clinic1,000 enrolled2 locationsNCT06315595
Recruiting
Phase 3

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Neoplasms
Janssen Research & Development, LLC663 enrolled163 locationsNCT07164443
Recruiting
Phase 1

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Metastatic Castration-resistant Prostate Neoplasms
Janssen Research & Development, LLC300 enrolled15 locationsNCT05818683
Recruiting
Phase 1Phase 2

Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy

Prostate CancerProstate Neoplasm
Washington University School of Medicine36 enrolled1 locationNCT03424850
Recruiting
Phase 2

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

Prostate CancerProstate CarcinomaProstate Neoplasm+12 more
Shehzad Basaria, M.D.60 enrolled1 locationNCT06957691
Recruiting

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

Breast CancerLiver CancerEsophageal Cancer+35 more
UMC Utrecht8,000 enrolled18 locationsNCT04075305
Recruiting

Novel Therapy Target in Metastatic Prostate Cancer

Prostate Neoplasms
Fudan University100 enrolled1 locationNCT05577689
Recruiting
Phase 4

Impact of Using the Airseal System With Ultra-low Pneumoperitoneum in Patients Undergoing Robot-assisted Radical Prostatectomy: A Prospective, Comparative, Randomized Clinical Study.

Quality of Life (QOL)Prostate CarcinomaProstate Neoplasm+1 more
Brazilian Institute of Robotic Surgery200 enrolled2 locationsNCT06784986
Recruiting
Not Applicable

Evaluating the Impact of Financial Navigation on Financial Catastrophe and Distress for Cancer Care

Breast NeoplasmProstate NeoplasmColon Neoplasm+1 more
Northwestern University200 enrolled2 locationsNCT06630962
Recruiting
Not Applicable

MRI-targeted Biopsy of the Prostate: Software Versus Visual Registration in the Accuracy of Prostate Cancer Detection

Prostate CancerProstate Neoplasm
Universitaire Ziekenhuizen KU Leuven96 enrolled1 locationNCT03819751
Recruiting

Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression

Prostate CancerObesityProstate Neoplasm+2 more
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico25 enrolled1 locationNCT06292897
Recruiting
Not Applicable

Effectiveness of Focal Therapy in Men With Prostate Cancer

Prostate CancerProstate Neoplasm
Radboud University Medical Center356 enrolled5 locationsNCT06223295